This review focuses on the underlying rationale for the use of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC) in the treatment of patients with primary gastrointestinal tumors with metastatic peritoneal disease.
Peter Thomas, PhD
Advertisement
Articles by Peter Thomas, PhD
Advertisement
Latest Updated Articles
Gastrointestinal Cancers With Peritoneal Carcinomatosis: Surgery and Hyperthermic Intraperitoneal ChemotherapyPublished: July 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
2
Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers
3
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
4
Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
5
